Skip to main content

KabiCare Patient Support Program forTYENNE® (tocilizumab-aazg)

TYENNE® (tocilizumab-aazg) is an FDA-approved biosimilar to Actemra® (tocilizumab) that addresses patients’ and prescribers’ core needs.1

First approved in 2023 in the European Union, TYENNE is indicated for treatment of:

  • Rheumatoid arthritis in adults
  • Giant cell arteritis in adults
  • Polyarticular juvenile idiopathic arthritis in patients ≥ 2 years of age
  • Systemic juvenile idiopathic arthritis in patients ≥ 2 years of age

Learn More About TYENNE (Opens in a New Window)

For more information about Biosimilars please visit our website: BioSpecialized (Opens in a New Window)

Reference 1: TYENNE (tocilizumab-aazg) injection prescribing information. Lake Zurich, IL: Fresenius Kabi USA, LLC; 2024

Please see the Full Prescribing Information, including the boxed WARNING, for TYENNE (tocilizumab-aazg) (PDF Opens in a New Window).

Important Safety Information

Program Support Areas

Learn more about the program support for TYENNE offered through KabiCare by selecting an area of support below:

KabiCare is here to offer you support and assistance, from diagnosis through your treatment and care.

There are several ways to enroll in the programs provided by KabiCare. Your healthcare provider can enroll you in the KabiCare Patient Support Program, or you can download the enrollment form (PDF Opens in a New Window) and begin completing it yourself. Your completed enrollment form can be submitted to KabiCare online by your HCP, or by fax. Once enrolled, you can opt-in for Nurse Support and note any communication preferences that the KabiCare Patient Support Guide should be aware of.

Click here to download the enrollment form. (PDF Opens in a New Window)

Who is Your Patient Support Guide?

Your KabiCare Patient Support Guide is someone who will be available to support you through the enrollment process and will work closely with you and your healthcare provider(s) to help navigate your insurance, financial assistance, and medication access needs to simplify your treatment journey. Getting answers to your questions is just a phone call away at 1-833-KABICARE (1-833-522-4227)

Welcome Packet

A Welcome Packet will be mailed or emailed to you once enrollment is complete. Inside the kit you will find important information about TYENNE and the KabiCare Patient Support Program. You will also receive a Welcome Call from a Patient Support Guide who will review the Welcome Packet materials with you and help answer questions about TYENNE.

KabiCare can help you navigate insurance processes and provide information related to your insurance coverage. After enrollment in KabiCare is complete you will receive a Welcome Call from a Patient Support Guide where you will have an opportunity to review your benefits and discuss other patient support program offerings you may be eligible to receive. Your Patient Support Guide is trained to assist you with questions about the KabiCare support programs available to you.

KabiCare can also help make sure your prescription gets to the right specialty pharmacy based on your healthcare provider’s preference or your insurance plan requirements.

Bridge to Therapy Program

The Bridge to Therapy Program ensures that you can receive TYENNE without delay while you are waiting for insurance approval. Eligibility* criteria apply.

*Eligibility criteria apply. Patients are not eligible for Bridge to Therapy Program support if the prescription is eligible to be reimbursed, in whole or in part, by any state or federal healthcare program.

KabiCare can help with enrolling you into additional assistance programs.

Commercial Copay Support

If you have commercial or private insurance, you may be eligible* for the copay program that lowers your out-of-pocket costs to as little as $0/month for treatment with an annual maximum.

Learn about the Copay Program or enroll your patient in the Copay Program only

Patient Assistance Program

If you do not have insurance and/or cannot afford your medication, you may be eligible for additional assistance through the Patient Assistance Program** or through independent nonprofit patient assistance programs. Eligibility criteria apply.‡

*Eligibility criteria apply. Patients are not eligible for commercial copay assistance if the prescription is eligible to be reimbursed, in whole or in part, by any state or federal healthcare program.

**Terms and conditions apply

‡Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Fresenius Kabi has no control over these programs.

Financial Assistance Resources

Non-Profit Foundations for Financial Assistance

 

Nurse Support

Once you are enrolled, KabiCare Nurse Educators are available to help you understand your disease, treatment, and prescribed medication. They can provide additional educational resources to you as needed or requested.

Nurse support provided by KabiCare is not meant to replace discussions with your healthcare provider regarding your care and treatment.

Why Enroll in KabiCare?

KabiCare is here to offer you support and assistance, from diagnosis through your treatment and care.

There are several ways to enroll in the programs provided by KabiCare. Your healthcare provider can enroll you online in the KabiCare Patient Support Program or by fax. Once enrolled, patients can note any communication preferences that the KabiCare Patient Support Guide should be aware of.

Talk to your doctor today about enrolling in KabiCare.

Expand

Important Safety Information

INDICATIONS

What does TYENNE treat?

TYENNE® (tocilizumab-aazg) is a prescription medicine called an interleukin-6 (IL-6) receptor antagonist. TYENNE is used:

  • To treat adults with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a disease modifying antirheumatic drug (DMARD) has been used and did not work well
  • To treat adults with giant cell arteritis (GCA)
  • To treat patients with active polyarticular juvenile idiopathic arthritis (PJIA) 2 years of age and older
  • To treat patients with active systemic juvenile idiopathic arthritis (SJIA) 2 years of age and older

It is not known if TYENNE is safe and effective in children with PJIA or SJIA under 2 years of age or in children with conditions other than PJIA or SJIA.

TYENNE can cause serious side effects

Serious Infections

TYENNE changes the way your immune system works. This can make you more likely to get infections or make any current infection worse. Some people have serious infections while taking TYENNE, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should assess you for TB before starting and during treatment with TYENNE.

Before starting TYENNE, tell your healthcare provider if you have:

  • an infection, think you may have an infection, are being treated for an infection, or get a lot of infections that return. Symptoms of an infection, with or without a fever, include sweating or chills; shortness of breath; warm, red or painful skin or sores on your body; feeling very tired; muscle aches; blood in phlegm; diarrhea or stomach pain; cough; weight loss; burning when you urinate or urinating more than normal
  • any of the following conditions that may give you a higher chance of getting infections: diabetes, HIV, or a weak immune system
  • tuberculosis (TB), or have been in close contact with someone with TB
  • live or have lived, or have traveled to certain parts of the United States where there is an increased chance of getting fungal infections. These parts include the Ohio and Mississippi River valleys and the Southwest
  • hepatitis B or have had hepatitis B

Who should not take TYENNE?

Do not take TYENNE if you are allergic to tocilizumab products, or any of the ingredients in TYENNE.

Be sure to talk to your healthcare provider if you see any signs of these serious side effects:

Tears (perforation) of the Stomach or Intestines

If you have diverticulitis (inflammation in parts of the large intestine), talk to your healthcare provider before taking TYENNE. Some people taking TYENNE may develop a hole in the wall of their stomach or intestines (also known as a perforation). This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.

Tell your healthcare provider right away if you see any of these side effects: fever, stomach-area pain that does not go away, or if you see a change in your bowel habits.

Liver problems (Hepatotoxicity)

Some people have experienced serious life-threatening liver problems, which required liver transplant or led to death. Your healthcare provider may tell you to stop taking TYENNE if you develop new or worsening liver problems during treatment with TYENNE. Tell your healthcare provider right away if you have any of the following symptoms:

  • feeling tired (fatigue)
  • lack of appetite for several days or longer (anorexia)
  • yellowing of your skin or the whites of your eyes (jaundice)
  • abdominal swelling and pain on the right side of the stomach-area
  • light colored stools
  • weakness
  • nausea and vomiting
  • confusion
  • dark “tea-colored” urine

Changes in Blood Test Results

Your healthcare provider should do blood tests before you start receiving TYENNE. If you have rheumatoid arthritis (RA) or giant cell arteritis (GCA), your healthcare provider should do blood tests 4 to 8 weeks after you start receiving TYENNE for the first 6 months and then every 3 months after that. If you have polyarticular juvenile idiopathic arthritis (PJIA) you will have blood tests done every 4 to 8 weeks during treatment. If you have systemic juvenile idiopathic arthritis (SJIA) you will have blood tests done every 2 to 4 weeks during treatment. These blood tests are to check for the following side effects of TYENNE:

  • Low neutrophil count: neutrophils are white blood cells that help the body fight infection
  • Low platelet count: platelets are blood cells that help with clotting, which stops bleeding
  • Increase in liver function test levels
  • Increase in blood cholesterol levels: your cholesterol levels should be checked 4 to 8 weeks after you start receiving TYENNE.

Your healthcare provider will determine how often you will have follow-up blood tests. Make sure you get all your follow-up blood tests done as ordered by your healthcare provider.

You should not receive TYENNE if your neutrophil and platelet counts are too low or your liver function test levels are too high. Changes in blood test results may cause your healthcare provider to stop your TYENNE treatment for a time or change your dose.

Cancer

TYENNE may increase your risk of certain cancers by changing the way your immune system works.

Hepatitis B Infection

If you have or are a carrier of the hepatitis B virus (a virus that affects the liver), the virus may become active while you use TYENNE. Your healthcare provider may do blood tests before you start treatment with TYENNE and while you are using TYENNE. Tell your healthcare provider if you have any signs of these symptoms:

  • feel very tired
  • skin or eyes look yellow
  • little or no appetite
  • vomiting
  • clay-colored bowel movements
  • fevers
  • chills
  • stomach discomfort
  • muscle aches
  • dark urine
  • skin rash

Serious Allergic Reactions Serious allergic reactions, including death, can happen with TYENNE. These reactions can happen with any infusion or injection of TYENNE, even if they did not occur with an earlier infusion or injection. Tell your healthcare provider before your next dose if you had hives, rash or flushing after your injection.

Contact 911 immediately, as well as your healthcare provider, if you experience any of these reactions:

  • shortness of breath or trouble breathing
  • swelling of the lips, tongue, or face
  • chest pain
  • feeling dizzy or faint
  • moderate or severe abdominal pain or vomiting

Nervous System Problems

While rare, Multiple Sclerosis has been diagnosed in people who take TYENNE. It is not known what effect TYENNE may have on some nervous system disorders.

What should I tell my healthcare provider before receiving TYENNE?

TYENNE may not be right for you. Before receiving TYENNE, tell your healthcare provider if you:

  • have an infection
  • have liver problems
  • have any stomach-area (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines
  • have had a reaction to tocilizumab products or any of the ingredients in TYENNE before
  • have or had a condition that affects your nervous system, such as multiple sclerosis
  • have recently received or are scheduled to receive a vaccine
  • plan to have surgery or a medical procedure
  • have any other medical conditions
  • plan to become pregnant or are pregnant. It is not known if TYENNE will harm your unborn baby.
  • plan to breast-feed or are breast-feeding. You and your healthcare provider should decide if you will take TYENNE or breast-feed. You should not do both.
  • are taking any medications, including prescription and nonprescription medicines, vitamins, and herbal supplements.

The most common side effects of TYENNE include:

  • upper respiratory tract infections (common cold, sinus infections)
  • headache
  • increased blood pressure (hypertension)
  • injection site reactions

TYENNE & Pregnancy

Tell your healthcare provider if you are planning to become pregnant, are pregnant, plan to breast-feed, or are breast-feeding. You and your healthcare provider should decide if you will take TYENNE or breast-feed. You should not do both.

Tell your healthcare provider if you have any side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Fresenius Kabi at 1-800-551-7176.

Please see full Prescribing Information and the Medication Guide, including Serious Side Effects, for more Important Safety Information.

Important Safety Information

INDICATIONS

What does TYENNE treat?

TYENNE® (tocilizumab-aazg) is a prescription medicine called an interleukin-6 (IL-6) receptor antagonist. TYENNE is used:

  • To treat adults with moderately to severely active rheumatoid arthritis (RA) after at least one other medicine called a disease modifying antirheumatic drug (DMARD) has been used and did not work well
  • To treat adults with giant cell arteritis (GCA)
  • To treat patients with active polyarticular juvenile idiopathic arthritis (PJIA) 2 years of age and older
  • To treat patients with active systemic juvenile idiopathic arthritis (SJIA) 2 years of age and older

It is not known if TYENNE is safe and effective in children with PJIA or SJIA under 2 years of age or in children with conditions other than PJIA or SJIA.

TYENNE can cause serious side effects

Serious Infections

TYENNE changes the way your immune system works. This can make you more likely to get infections or make any current infection worse. Some people have serious infections while taking TYENNE, including tuberculosis (TB), and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider should assess you for TB before starting and during treatment with TYENNE.

Before starting TYENNE, tell your healthcare provider if you have:

  • an infection, think you may have an infection, are being treated for an infection, or get a lot of infections that return. Symptoms of an infection, with or without a fever, include sweating or chills; shortness of breath; warm, red or painful skin or sores on your body; feeling very tired; muscle aches; blood in phlegm; diarrhea or stomach pain; cough; weight loss; burning when you urinate or urinating more than normal
  • any of the following conditions that may give you a higher chance of getting infections: diabetes, HIV, or a weak immune system
  • tuberculosis (TB), or have been in close contact with someone with TB
  • live or have lived, or have traveled to certain parts of the United States where there is an increased chance of getting fungal infections. These parts include the Ohio and Mississippi River valleys and the Southwest
  • hepatitis B or have had hepatitis B

Who should not take TYENNE?

Do not take TYENNE if you are allergic to tocilizumab products, or any of the ingredients in TYENNE.

Be sure to talk to your healthcare provider if you see any signs of these serious side effects:

Tears (perforation) of the Stomach or Intestines

If you have diverticulitis (inflammation in parts of the large intestine), talk to your healthcare provider before taking TYENNE. Some people taking TYENNE may develop a hole in the wall of their stomach or intestines (also known as a perforation). This happens most often in people who also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate.

Tell your healthcare provider right away if you see any of these side effects: fever, stomach-area pain that does not go away, or if you see a change in your bowel habits.

Liver problems (Hepatotoxicity)

Some people have experienced serious life-threatening liver problems, which required liver transplant or led to death. Your healthcare provider may tell you to stop taking TYENNE if you develop new or worsening liver problems during treatment with TYENNE. Tell your healthcare provider right away if you have any of the following symptoms:

  • feeling tired (fatigue)
  • lack of appetite for several days or longer (anorexia)
  • yellowing of your skin or the whites of your eyes (jaundice)
  • abdominal swelling and pain on the right side of the stomach-area
  • light colored stools
  • weakness
  • nausea and vomiting
  • confusion
  • dark “tea-colored” urine

Changes in Blood Test Results

Your healthcare provider should do blood tests before you start receiving TYENNE. If you have rheumatoid arthritis (RA) or giant cell arteritis (GCA), your healthcare provider should do blood tests 4 to 8 weeks after you start receiving TYENNE for the first 6 months and then every 3 months after that. If you have polyarticular juvenile idiopathic arthritis (PJIA) you will have blood tests done every 4 to 8 weeks during treatment. If you have systemic juvenile idiopathic arthritis (SJIA) you will have blood tests done every 2 to 4 weeks during treatment. These blood tests are to check for the following side effects of TYENNE:

  • Low neutrophil count: neutrophils are white blood cells that help the body fight infection
  • Low platelet count: platelets are blood cells that help with clotting, which stops bleeding
  • Increase in liver function test levels
  • Increase in blood cholesterol levels: your cholesterol levels should be checked 4 to 8 weeks after you start receiving TYENNE.

Your healthcare provider will determine how often you will have follow-up blood tests. Make sure you get all your follow-up blood tests done as ordered by your healthcare provider.

You should not receive TYENNE if your neutrophil and platelet counts are too low or your liver function test levels are too high. Changes in blood test results may cause your healthcare provider to stop your TYENNE treatment for a time or change your dose.

Cancer

TYENNE may increase your risk of certain cancers by changing the way your immune system works.

Hepatitis B Infection

If you have or are a carrier of the hepatitis B virus (a virus that affects the liver), the virus may become active while you use TYENNE. Your healthcare provider may do blood tests before you start treatment with TYENNE and while you are using TYENNE. Tell your healthcare provider if you have any signs of these symptoms:

  • feel very tired
  • skin or eyes look yellow
  • little or no appetite
  • vomiting
  • clay-colored bowel movements
  • fevers
  • chills
  • stomach discomfort
  • muscle aches
  • dark urine
  • skin rash

Serious Allergic Reactions Serious allergic reactions, including death, can happen with TYENNE. These reactions can happen with any infusion or injection of TYENNE, even if they did not occur with an earlier infusion or injection. Tell your healthcare provider before your next dose if you had hives, rash or flushing after your injection.

Contact 911 immediately, as well as your healthcare provider, if you experience any of these reactions:

  • shortness of breath or trouble breathing
  • swelling of the lips, tongue, or face
  • chest pain
  • feeling dizzy or faint
  • moderate or severe abdominal pain or vomiting

Nervous System Problems

While rare, Multiple Sclerosis has been diagnosed in people who take TYENNE. It is not known what effect TYENNE may have on some nervous system disorders.

What should I tell my healthcare provider before receiving TYENNE?

TYENNE may not be right for you. Before receiving TYENNE, tell your healthcare provider if you:

  • have an infection
  • have liver problems
  • have any stomach-area (abdominal) pain or been diagnosed with diverticulitis or ulcers in your stomach or intestines
  • have had a reaction to tocilizumab products or any of the ingredients in TYENNE before
  • have or had a condition that affects your nervous system, such as multiple sclerosis
  • have recently received or are scheduled to receive a vaccine
  • plan to have surgery or a medical procedure
  • have any other medical conditions
  • plan to become pregnant or are pregnant. It is not known if TYENNE will harm your unborn baby.
  • plan to breast-feed or are breast-feeding. You and your healthcare provider should decide if you will take TYENNE or breast-feed. You should not do both.
  • are taking any medications, including prescription and nonprescription medicines, vitamins, and herbal supplements.

The most common side effects of TYENNE include:

  • upper respiratory tract infections (common cold, sinus infections)
  • headache
  • increased blood pressure (hypertension)
  • injection site reactions

TYENNE & Pregnancy

Tell your healthcare provider if you are planning to become pregnant, are pregnant, plan to breast-feed, or are breast-feeding. You and your healthcare provider should decide if you will take TYENNE or breast-feed. You should not do both.

Tell your healthcare provider if you have any side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Fresenius Kabi at 1-800-551-7176.

Please see full Prescribing Information and the Medication Guide, including Serious Side Effects, for more Important Safety Information.